Helping Clinicians Make Better Decisions





Clinical Reference Guide

Period of Detection

F

Period of Detection

Patients exhibit varying periods of detection for any given drug. Periods of detection provide general estimates for the period of time in which a drug is expected to be detected in a given matrix. This time frame depends on many factors, including thresholds, analytes tested, dosing regimen, etc.

The windows of detection are different for each specimen type. Typically periods of detection are shortest for blood and oral fluid, longer for urine, and longest for hair. Various factors will influence the period of drug detection: drug half-life, specimen type, test threshold, whether parent drug and metabolites are included in testing, patient renal and hepatic function, drug plasma-protein binding, nutritional status, route of administration, drug absorption, genetic differences, drug interactions, food interactions, age, body composition, etc. Drugs taken infrequently on an as-needed (PRN) basis are likely to be detected for shorter periods than drugs taken chronically. All published periods of detection are gross estimates, as it is impossible to predict exactly how long a drug will remain detectable for any one patient.^{1,2}

A. Oral Fluid

Drugs present in oral fluid roughly mirror drug presence in blood, although concentrations will not generally show a direct correlation. Drugs may be detectable in oral fluid as early as 15 minutes following ingestion. On the other hand, medications may not be detectable in urine for 2-6 hours post ingestion.³⁻⁹ Medications which are chronically administered in pain management may be detectable in oral fluid for a period up to 48 hours. Studies have observed extended oral fluid detection of 6-monoacetylmorphine (heroin metabolite), methadone, amphetamine, and methamphetamine for up to 8 days in patients on an observed detoxification unit; however, these extended periods of detection are atypical in the context of other oral fluid studies.^{10,11} Use of medications on an infrequent basis (for example, taken at bedtime, but not every day) shortens the detection period.

B. Blood

As with oral fluid, the period of detection of a drug in blood is shorter than urine and will vary significantly from patient to patient. Detection of drugs in blood is almost always limited to current use. The detection period will depend on medication dose, dosing frequency, drug half-life, and pharmacokinetic parameters of the patient.¹² About 97% of a drug dose will be eliminated from the body after five half-lives.¹³

C. Urine

The period of detection for drugs in urine typically exceeds that of oral fluid and blood. Lipophilic drugs which readily deposit into fat (such as marijuana, diazepam, methadone, and others) may exhibit notably longer periods of detection.^{2,7,13} In addition, many drug metabolites exhibit longer elimination half-lives than parent drug. Testing for metabolites in urine may therefore extend the detection window. This is true for illicit drugs such as marijuana and cocaine, as well as prescription medications like opioids and benzodiazepines.¹³⁻¹⁵ Testing for opioid normetabolites may extend the detection period for this drug class.^{14,15} Periods of detection may also be longer when using gas chromatography/mass spectrometry (GC/MS) or liquid chromatography/tandem mass spectrometry (LC/MS/MS) methods compared to immunoassay, due to increased sensitivity and lower testing thresholds. Period of detection estimates for urine with typical drug use are presented in Table 6.1.

D. Special Note on Marijuana

The detection time for marijuana in urine depends heavily on the body composition of the patient and the frequency of use. Daily use of marijuana is expected to be detectable in urine for a period up to 10 days; light use (such as one joint) may only be detectable for up to 3 days.¹⁶ One study demonstrated that 73% of 37 chronic marijuana users had THC concentrations below a cutoff of 15 ng/mL within 2 weeks of last ingestion.¹⁷

Patients with a large amount of adipose tissue may store marijuana and excrete metabolites for a longer period of time, especially after abnormally heavy use over a chronic period. In such rare cases, marijuana has been

F-1

reported with a period of detection up to 30 days, with the longest period published as 95 days. Such a long

period of detection is the exception, not the rule.^{2,12,16}

Table 6.1: Drug Periods of Detection in Urine*

DRUG CLASS	DRUG	REPORTING LIMIT	PERIOD OF DETECTION
Amphetamines	Amphetamine Methamphetamine MDMA (Ecstasy) MDEA (Eve) MDA (Adam) Phentermine	250 ng/mL 250 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL	Up to 5 days Up to 5 days
Anticonvulsants	Lamotrigine Levetiracetam Oxcarbazepine Topiramate	500 ng/mL 500 ng/mL 500 ng/mL 500 ng/mL	Up to 10 days Up to 3 days Up to 3 days Up to 10 days
Antipsychotics	Aripiprazole Clozapine Haloperidol Lurasidone Olanzapine Paliperidone Quetiapine Risperidone Ziprasidone	10 ng/mL 50 ng/mL 1 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL	Up to 7 days Up to 5 days Up to 10 days Up to 5 days Up to 7 days
Barbiturates	Amobarbital Butalbital Pentobarbital Phenobarbital Secobarbital	200 ng/mL 200 ng/mL 200 ng/mL 200 ng/mL 200 ng/mL	Up to 10 days Up to 10 days
Benzodiazepines	Alprazolam Chlordiazepoxide Clonazepam Clorazepate Diazepam Flurazepam Lorazepam Oxazepam Temazepam	50 ng/mL 50 ng/mL 50 ng/mL 50 ng/mL 50 ng/mL 50 ng/mL 50 ng/mL 50 ng/mL 50 ng/mL	Up to 10 days Up to 10 days
Illicit Drugs/ Drugs of Concern	Cocaine Heroin Kratom Marijuana Phencyclidine Synthetic Cannabinoids Synthetic Cathinones	50 ng/mL 10 ng/mL 10 ng/mL 5 ng/mL 25 ng/mL 2 ng/mL 25 ng/mL	Up to 5 days Up to 24 hours Up to 5 days Up to 10 days** Up to 5 days Up to 10 days Up to 10 days Up to 5 days
Miscellaneous	Armodafinil/Modafinil Bupropion Buspirone Clonidine Dextromethorphan Ethanol Ethyl Glucuronide Ethyl Sulfate Gabapentin Guanfacine Hydroxyzine Ketamine Methylphenidate Mirtazapine Nicotine Pregabalin	100 ng/mL 50 ng/mL 25 ng/mL 50 ng/mL 50 ng/mL 10 mg/dL 500 ng/mL 200 ng/mL 50 ng/mL 50 ng/mL 10 ng/mL 10 ng/mL 125 ng/mL 5 mcg/mL	Up to 5 days Up to 7 days Up to 3 days Up to 3 days Up to 5 days Up to 8 hours Up to 3 days Up to 3 days Up to 3 days Up to 5 days Up to 5 days Up to 7 days Up to 3 days Up to 3 days Up to 3 days Up to 3 days Up to 5 days

DRUG CLASS	DRUG	REPORTING LIMIT	PERIOD OF DETECTION
Miscellaneous (cont.)	Trazodone	100 ng/mL	Up to 3 days
Mixed Opioid Agonists/ Antagonists	Butorphanol Nalbuphine Pentazocine	1 ng/mL 1 ng/mL 25 ng/mL	Up to 2 days Up to 2 days Up to 3 days
Muscle Relaxants	Baclofen Carisoprodol Chlorzoxazone Cyclobenzaprine Dantrolene Meprobamate Metaxalone Methocarbamol Tizanidine	500 ng/mL 200 ng/mL 50 ng/mL 10 ng/mL 50 ng/mL 200 ng/mL 50 ng/mL 500 ng/mL 5 ng/mL	Up to 3 days Up to 5 days Up to 2 days Up to 5 days Up to 7 days Up to 7 days Up to 5 days Up to 3 days Up to 2 days Up to 2 days
Opioid Antagonists	Naloxone Naltrexone	1 ng/mL 1 ng/mL	Up to 3 days Up to 5 days
Opioids	Buprenorphine Codeine Dihydrocodeine Fentanyl Hydrocodone Hydromorphone Levorphanol Meperidine Methadone Morphine Oxycodone Oxymorphone Tapentadol Tramadol	1 ng/mL 100 ng/mL 100 ng/mL 5 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL 100 ng/mL	Up to 7 days Up to 5 days
Sedative Hypnotics	Eszopiclone/Zopiclone Zaleplon Zolpidem	4 ng/mL 4 ng/mL 4 ng/mL	Up to 24 hours Up to 24 hours Up to 3 days
SNRIs	Desvenlafaxine Duloxetine Milnacipran/Levomilnacipran Venlafaxine	50 ng/mL 5 ng/mL 5 ng/mL 5 ng/mL 5 ng/mL	Up to 7 days Up to 7 days Up to 7 days Up to 7 days Up to 7 days
SSRIs	Citalopram Fluoxetine Paroxetine Sertraline	50 ng/mL 50 ng/mL 50 ng/mL 50 ng/mL	Up to 7 days Up to 7 days Up to 7 days Up to 7 days
Tricyclic Antidepressants	Amitriptyline Clomipramine Desipramine Doxepin Imipramine Nortriptyline Protriptyline Trimipramine	10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL	Up to 7 days Up to 7 days

*Note: Drug detection periods will vary, depending on whether the drug is taken intermittently or chronically, and on many patient-specific factors. The above period of detection estimates are not intended to cover implants or long-acting injectables.

**Please refer to the Special Note on Marijuana section for further information related to its expected period of detection.

REFERENCES:

F-3

- 1. Katz N, Fanciullo GJ. Role of urine toxicology testing in the management of chronic opioid therapy. *Clin J Pain*. 2002;18:S76-82.
- 2. Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. *Ther Drug Monit.* 2004;26(2):200-5.
- 3. Foltz RL, Fentiman AF, Foltz RB. GC/MS assays for abused drugs in body fluids. *NIDA Res Monogr.* 1980;32:1-198.
- 4. Smith ML, Shimomura ET, Summers J, et al. Urinary excretion profiles

for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. *J Anal Toxicol.* 2001;25(7):504-14.

- Rohrig TP, Moore C. The determination of morphine in urine and oral fluid following ingestion of poppy seeds. *J Anal Toxicol*. 2003;27:449-52.
- Cone EJ, Huestis MA. Interpretation of oral fluid tests for drugs of abuse. Ann N Y Acad Sci. 2007;1098:51-103.
- 7. Allen KR. Screening for drugs of abuse: which matrix, oral fluid or urine? Ann Clin Biochem. 2011;48:531-41.

- Cone EJ, Heltsley R, Black DL, Mitchell JM, Lodico CP, Flegel RR. Prescription Opioids. I. Metabolism and excretion patterns of oxycodone following controlled single dose administration. J Anal Toxicol. 2013;37(5):255-64.
- Cone EJ, Heltsley R, Black DL, Mitchell JM, Lodico CP, Flegel RR. Prescription Opioids. II. Metabolism and excretion patterns of hydrocodone in urine following controlled single-dose administration. *J Anal Toxicol.* 2013;37(8):486-94.
- Vindenes V, Enger A, Nordal K, Johansen U, Christophersen AS, Øiestad EL. Very long detection times after high and repeated intake of heroin and methadone, measured in oral fluid. Scan J of For Sci. 2014;20(2):34-41.
- Andås HT, Enger A, Øiestad AML, et al. Extended detection of amphetamine and methamphetamine in oral fluid. *Ther Drug Monit*. 2016;38:114-9.
- Gourlay DL, Heit HA, Caplan YH. Urine drug testing in clinical practice: the art and science of patient care. 6th ed. Stamford, CT: PharmaCom Group, Inc.;2015:1-32.
- Hawks RL, Chiang CN. Urine testing for drugs of abuse. NIDA Res Monogr. 1986;73:1-114.
- Heltsley R, Zichterman A, Black DL, et al. Urine drug testing of chronic pain patients. II. Prevalence patterns of prescription opiates and metabolites. *J Anal Toxicol.* 2010;34:32-8.
- DePriest A, Heltsley R, Black DL, et al. Urine drug testing of chronic pain patients. III. Normetabolites as biomarkers of synthetic opioid use. *J Anal Toxicol.* 2010;34:444-9.
- 16. Heit HA, Gourlay DL. Urine drug testing in pain medicine. *J Pain Symptom Manage*. 2004;27(3):260-7.
- Lewis J, Molnar A, Allsop D, Copeland J, Fu S. Rapid elimination of Carboxy-THC in a cohort of chronic cannabis users. *Int J Legal Med.* 2016;130(1):147-152.